XenoTherapeutics Overview
- Founded
- 2016
- Status
- Private
- Employees
- 10
- Latest Deal Type
- Grant
- Investors
- 3
XenoTherapeutics General Information
Description
Operator of a gene therapy company intended to develop personalized cells, tissues, and organs for transplantation. The company's first product is derived from genetically engineered, immune-corrected pigs, enabling victims with severe and extensive burns in Phase I clinical trial to access an affordable, safe and plentiful treatment whenever is necessary.
Contact Information
Website
Ownership Status
Privately Held (no backing)
Financing Status
Corporation
Primary Industry
Therapeutic Devices
Other Industries
Biotechnology
Primary Office
- PO Box 1362
- Londonderry, NH 03053
- United States
+1 (617) 000-0000
XenoTherapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Grant | Completed | Startup | ||||
| 2. Grant | 27-Jan-2017 | 0000 | Completed | Startup | ||
| 1. Grant | 19-May-2016 | Completed | Startup |
XenoTherapeutics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Operator of a gene therapy company intended to develop personalized cells, tissues, and organs for transplantation. The
Therapeutic Devices
Londonderry, NH
10
As of 2020
00000
000000
eprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat
0000 000000000
Stockholm, Sweden
00
As of 0000
0000
0000000000 0
0000
00000000
elit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, su
0000000000000
Cambridge, MA
00
As of 0000
00000
00000000000
00000
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialXenoTherapeutics Competitors (4)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| ITBMed | Venture Capital-Backed | Stockholm, Sweden | 00 | 0000 | 0000000000 0 | 0000 |
| 00000000 | Venture Capital-Backed | Cambridge, MA | 00 | 00000 | 00000000000 | 00000 |
| 000000 00000000000 | Formerly VC-backed | Silver Spring, MD | 000 | 00000 | 000000 - 000 | 00000 |
| 000000000 | Corporation |
XenoTherapeutics Executive Team (5)
XenoTherapeutics Board Members (3)
| Name | Representing | Role | Since |
|---|---|---|---|
| Michael Yaremchuk | XenoTherapeutics | Trustee of Board | 000 0000 |
| Paul Barrett | XenoTherapeutics | Chairman | 000 0000 |
XenoTherapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialXenoTherapeutics Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| John Flatley Company | Corporation | 000 0000 | 000000 0 | ||
| MassChallenge | Accelerator/Incubator | 000 0000 | 000000 0 | ||
| Columbia Technology Ventures | University | Minority | 000 0000 | 000000 0 |